Middle-eastern countries have been infusing the growth in the oncology drugs market, while their regulatory steps have made this space more lucrative for drug manufacturers from across the globe. 

This report gives macro as well as micro level view of the middle-east oncology market including approved drugs, relevant pharma programs and govt. initiatives. It also touches upon shortened approval timeline, faster local registrations and reimbursement aspects that smoothen the market access process.